Dr John M

cardiac electrophysiologist, cyclist, learner

  • Home
  • About
    • About Me
    • About the Blog
      • General Cardiology and Internal Medicine
    • Six Reasons why I Blog
    • What’s Electrophysiology?
    • ICD/Pacemaker
    • Electrophysiology Column / Medscape
    • Contact
  • Afib
    • AFib
    • AF in Athletes
    • The best tool to treat AF
    • Know your CHADS-VASC Score
    • 3 non-warfarin anticoagulants
    • AF ablation
      • 13 things to know about AF
      • Atrial Fib Ablation -2012 Update
      • Gender-Spec results of AF ablation
    • Female gender and stroke risk in AF
    • My AF Story
  • Heart Healthy
    • Heart Disease (by DrJohnM)
    • Healthy Living
    • Exercise
    • Nutrition
    • inflammation
  • Policy
    • Policy
    • Health Care
    • Health Care Reform
  • Doctoring
    • Doctoring
    • Knowledge
    • Reflection
    • General Medicine
      • Does your cholesterol level matter?
    • General Cardiolgy – Medicine
      • What is a normal heart rate?
      • Cardiology/Internal Med
      • General Cardiology
      • Athletic heart
        • The ECG of an athlete
      • General Medicine
      • Stroke
      • Statins
  • Cycling
    • DrJohnM on Cycling
    • How I became a bike racer
    • My top 12 Likes on Cycling
    • Cyclocross
      • A CX-Primer
    • Fitness
    • Athletic heart
    • The Mysterious Athletic Heart

Possible clot issue on replacement aortic valves slows momentum of TAVR

October 10, 2015 By Dr John

The next frontier in cardiology is the replacement of cardiac valves via catheters rather than open-chest surgery. This new branch of cardiology is called “structural” cardiology. Trainees do entire “structural” fellowships in which they learn to do things with catheters that surgeons once did with open chest techniques.

You may have heard about TAVR–or transcatheter aortic valve replacement. This procedure was pioneered in Europe, and now more than 200,000 cases have been done worldwide. We have a nascent but successful TAVR program at my hospital.

In the US, TAVR is approved only for patients with high surgical risk. But that may change soon. After a 4-year experience, improved iterations of the valves, and emerging data on TAVR safety and efficacy, momentum is building to expand TAVR to lower-risk patients.

That momentum slowed this week. A small but compelling study (published in the New England Journal of Medicine) found that up to 40% of replacement aortic valves made from pig or cow tissue, did not open properly–possibly related to blood clots on the leaflets.

This was an unexpected and shocking finding. And it was made possible because of a novel imaging technique called 4-D CT scanning. Standard ultrasound (echo) did not have the resolution to see the problem.

The New England Journal of Medicine published two editorials along with the paper. Two experts in the field called the news “extremely important” while FDA representatives said the valves “remained safe and effective and that findings to date concerning reduced leaflet motion have not changed the overall favorable benefit–risk balance for these valves when they are used for their approved indications.”

This could be a big story. Medical dogma has long-held that tissue valves—because they are tissue and not metal—do not require anticoagulant therapy. This is the essence of their advantage over metal valves. Patients faced with valve replacement make the trade-off of less durability with tissue valves because they are told they won’t need warfarin. Add to that, tissue valves can now be placed via a catheter.

I covered these new findings in my column this week over at theHeart.org | Medscape Cardiology. The title and link are here:

Possible Clots on Bioprosthetic Aortic Valves: Potential Roadblock for Structural Cardiology

JMM

P.S. To read stories on Medscape, you have to register with an email. It’s free.

  • Email
  • LinkedIn
  • Facebook
  • Twitter
  • More
  • Reddit

Related posts:

  1. Crowdsourcing a consumer safety issue — EMI interference and cardiac devices
  2. New post up on theHeart.org/Medscape Cardiology…Where is the progress in Cardiology?
  3. Why shouldn’t Cardiology lead the way in shared decsion-making?
  4. Pacemkers that never need generator replacement?

Filed Under: Doctoring, General Cardiology Tagged With: TAVR

John Mandrola, MD

Welcome, Enjoy, Interact. john-mandrola I am a cardiac electrophysiologist practicing in Louisville KY. I am also a husband to a palliative care doctor, a father, a bike racer, and a regular columnist at theHeart.org | Medscape

My First Book is Now Available…

Email Newsletter

Search the Site

Categories

Find me on theheart.org | Medscape Cardiology

  • Electrophysiology commentary on Medscape/Cardiology

Mandrola on Medscape

  • My Medscape column on general medical matters

For patients...Educational posts

  • 13 things to know about Atrial Fibrillation — 2014
  • A new cure of AF
  • Adding a new verb to doctoring: To deprescribe is to do a lot
  • AF ablation — 2015 A Cautionary Note
  • AF Ablation in 2012–An easier journey?
  • Atrial Flutter — 15 facts you may want to know.
  • Benign PVCs: A heart rhythm doctor’s approach.
  • Caution with early Cardioversion
  • Decisions of 2 low-risk cases of PAF
  • Defining success in AF ablation in 2014
  • Four commonly asked questions on AF ablation
  • Inflammation and AF — Get off the gas
  • Ten things to expect after AF ablation
  • The medical decsion as a gamble
  • The most important verb in our health crisis
  • Wellness Requires Ownership

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.